Magnus Medical
Magnus Medical develops the SAINT neuromodulation system, which utilizes structural and functional MRI to identify optimal therapy targets in the brain for personalized treatment of severe depression. By applying a non-invasive pattern of repetitive magnetic pulses, SAINT modifies brain network activity, effectively restoring mood balance in individuals with intractable neurological and psychiatric disorders.
- Biotechnology
- Digital Health
- Healthcare Technology
- Medical Devices
Funding
Raised to date
$25MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Severe depression is caused by identifiable changes in brain networks, but current treatments often lack precision and effectiveness, leaving many individuals with intractable symptoms. Identifying the optimal therapy target in the brain for each person remains a challenge.
Solution
Magnus Medical's SAINT neuromodulation system uses structural and functional MRI to identify personalized therapy targets in the brain for treating severe depression. The system applies a non-invasive pattern of repetitive magnetic pulses to modify brain network activity, aiming to restore mood balance. By precisely stimulating the identified target, SAINT seeks to address the underlying neurological changes associated with major depression. The technology represents a next-generation approach to neuromodulation, designed to improve the quality of life for individuals with mental health conditions.
Target Audience
The primary users are medical professionals offering treatment for severe depression, including physicians, hospitals, and clinical research institutions.
Features
- Utilizes structural and functional MRI to map individual brain networks and pinpoint optimal stimulation targets.
- Employs a specialized, non-invasive pattern of repetitive magnetic pulses for targeted neuromodulation.
- Aims to modify activity in brain networks related to major depression.